4SC achieves hat trick of resminostat successes: RCC, CRC and now Hodgkin’s
This article was originally published in Scrip
Executive Summary
German biotechnology firm 4SC will "discuss the path towards registration with the regulatory agencies in the near future" for its oral pan-histone deacetylase (HDAC) inhibitor, resminostat, after the product met the primary endpoint in a Phase II trial in Hodgkin's lymphoma (HL). The company added that it now had the information it needed to initiate the next development steps for the compound.